NEW YORK (AP) _ Intra-Cellular Therapies Inc. (ITCI) on Tuesday reported a loss of $76.9 million in its third quarter.

The New York-based company said it had a loss of 95 cents per share.

The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 89 cents per share.

The biopharmaceutical company posted revenue of $22.2 million in the period, which topped Street forecasts. Three analysts surveyed by Zacks expected $22 million.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ITCI at https://www.zacks.com/ap/ITCI

Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News